Bayer buys Cambridge cell therapy startup BlueRock at $1B value
August 08, 2019 at 10:09 AM EDT
The German-based drug giant has doubled down on one of its previous investments, announcing a deal to acquire the remainder of the stake in BlueRock Therapeutics for $600 million.
